Tough Q3 For Roche But Diagnostics Soften The Blow
Biosimilar Competition Keeps Biting
Executive Summary
The Swiss major's old guard of oncology products continue to falter but Roche's new wave of treatments is helping to keep the financials fairly healthy.
You may also be interested in...
Bayer Boosts Gene Therapy Presence With AskBio Buy
After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.
Novartis Takes Huntington's Path With SMA Therapy Branaplam
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
Need a specific report? 1000+ reports available
Buy Reports